Nine Chapters Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Nine Chapters Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-9,900	Closed	-$376K	–	1221
2015 Q1	$376K	Buy	9,900 +300	+3%	+$10.3K	0.03%	665
2014 Q4	$272K	Buy	+9,600	New	+$267K	0.02%	710

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Nine Chapters Capital Management's PTLA Position: Q2 2015 in Review

Nine Chapters Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2015, closing a stake of 9,900 shares — an estimated $376K sold.

Nine Chapters Capital Management first reported a position in PTLA in Q4 2014 and held it in 2 quarters. The position peaked at $376K in Q1 2015. 160 funds tracked by Wall St. Rank hold PTLA as of Q2 2015.

Nine Chapters Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 9,900 Portola Pharmaceuticals, Inc. shares in Q2 2015, an estimated $376K.
Nine Chapters Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Nine Chapters Capital Management's Portola Pharmaceuticals, Inc. position peaked at $376K in Q1 2015.
160 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2015.

Based on Nine Chapters Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.